
## **Toshiro Shinke**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1124792/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A serial optical frequency-domain imaging study of early and late vascular responses to bioresorbable-polymer sirolimus-eluting stents for the treatment of acute myocardial infarction and stable coronary artery disease patients: results of the MECHANISM-ULTIMASTER study. Cardiovascular Intervention and Therapeutics. 2022. 37, 281-292.	2.3	8
2	Feasibility, Safety, and Long-Term Outcomes of Zero-Contrast Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. Circulation Journal, 2022, 86, 787-796.	1.6	6
3	Development, validation, and reproducibility of the pullback pressure gradient (PPG) derived from manual fractional flow reserve pullbacks. Catheterization and Cardiovascular Interventions, 2022, 99, 1518-1525.	1.7	8
4	Coronary High-Intensity Plaques at T1-weighted MRI in Stable Coronary Artery Disease: Comparison with Near-Infrared Spectroscopy Intravascular US. Radiology, 2022, 302, 557-565.	7.3	9
5	Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nature Reviews Cardiology, 2022, 19, 684-703.	13.7	106
6	Comparison of serial optical coherence tomography imaging following aggressive stent expansion technique: insight from the MECHANISM study. International Journal of Cardiovascular Imaging, 2021, 37, 419-428.	1.5	2
7	Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipidâ€lowering therapy. Journal of Diabetes Investigation, 2021, 12, 1015-1024.	2.4	5
8	The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial. BMC Cardiovascular Disorders, 2021, 21, 92.	1.7	6
9	Duration of Hyperemia With Intracoronary Administration of Papaverine. Journal of the American Heart Association, 2021, 10, e018562.	3.7	19
10	Clinical predictors for bradycardia and supraventricular tachycardia necessitating therapy in patients with unexplained syncope monitored by insertable cardiac monitor. Clinical Cardiology, 2021, 44, 683-691.	1.8	4
11	Ultra-minimum contrast percutaneous coronary intervention for a patient with complex coronary artery disease and end-stage diabetic nephropathy. Journal of Cardiology Cases, 2021, 23, 290-293.	0.5	1
12	Hemodynamic changes during transcatheter atrial septal defect closure predict midterm heart failure deterioration in adults. Catheterization and Cardiovascular Interventions, 2021, 98, E715-E723.	1.7	1
13	Efficacy of optical frequency domain imaging in detecting peripheral artery disease: the result of a multi-center, open-label, single-arm study. Heart and Vessels, 2021, 36, 818-826.	1.2	6
14	Final 5-Year Results in Randomized Japanese Patients Implanted With a Thin-Strut, Bioabsorbable, Polymer-Coated, Everolimus-Eluting SYNERGY Stent (From the EVOLVE II Study). Circulation Reports, 2021, 3, 9-17.	1.0	1
15	Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study. BMJ Open, 2020, 10, e028831.	1.9	17
16	Acute myocardial infarction caused by persistent coronary spasm associated with high-grade macrophage accumulation. BMJ Case Reports, 2020, 13, e234502.	0.5	3
17	Vascular response to pacificaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall) Tj ETQq1 1	0.784314 1.5	rgBT /Overloo 4
18	Impact of CD14 ++ CD16 + monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients. Atherosclerosis, 2018, 269, 245-251.	0.8	32

TOSHIRO SHINKE

#	Article	IF	CITATIONS
19	Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry. Cardiovascular Intervention and Therapeutics, 2018, 33, 360-371.	2.3	3
20	Comparison of the relationship between multiple parameters of glycemic variability and coronary plaque vulnerability assessed by virtual histology–intravascular ultrasound. Journal of Diabetes Investigation, 2018, 9, 610-615.	2.4	12
21	Data on impact of monocytes and glucose fluctuation on plaque vulnerability in patients with coronary artery disease. Data in Brief, 2018, 18, 172-175.	1.0	0
22	Favorable early vessel healing after everolimus-eluting stent implantation: 3-, 6-, and 12-month follow-up of optical coherence tomography. Journal of Cardiology, 2018, 72, 193-199.	1.9	6
23	Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. Journal of Cardiology, 2018, 72, 403-410.	1.9	1
24	Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT. Journal of Cardiology, 2017, 70, 530-536.	1.9	9
25	Impact of CD14++CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study. Cardiovascular Diabetology, 2017, 16, 96.	6.8	30
26	Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography. Cardiovascular Diabetology, 2016, 15, 79.	6.8	36
27	β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes. Biochemical and Biophysical Research Communications, 2016, 475, 322-328.	2.1	79
28	Impact of final kissing balloon inflation on vessel healing following drug-eluting stent implantation: Insight from the optical coherence tomography sub-study of the J-REVERSE trial. Journal of Cardiology, 2016, 68, 504-511.	1.9	13
29	Comparison of Everolimus- versus Sirolimus-eluting stents in the provisional Bifurcation stenting guided by intravascular ultrasound: mid-term results of the J-REVERSE registry. Cardiovascular Intervention and Therapeutics, 2016, 31, 1-12.	2.3	2
30	Differences in Vessel Healing Between Sirolimus- and Everolimus-Eluting Stent Implantation for Bifurcation Lesions: The J-REVERSE Optical Coherence Tomography Substudy. Canadian Journal of Cardiology, 2016, 32, 384-390.	1.7	6
31	Optical coherence tomography study of chronic-phase vessel healing after implantation of bare metal and paclitaxel-eluting self-expanding nitinol stents in the superficial femoral artery. Journal of Cardiology, 2016, 67, 424-429.	1.9	12
32	Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography. Cardiovascular Diabetology, 2015, 14, 78.	6.8	40
33	Effect of Daily Glucose Fluctuation on Coronary Plaque Vulnerability in Patients Pre-Treated With Lipid-Lowering Therapy. JACC: Cardiovascular Interventions, 2015, 8, 800-811.	2.9	64
34	Serial Optical Coherence Tomography Evaluation at 6, 12, and 24 Months After Biolimus A9-Eluting Biodegradable Polymer-Coated Stent Implantation. Canadian Journal of Cardiology, 2015, 31, 980-988.	1.7	14
35	Reconstruction of an Extracardiac Aortocoronary Collateral and Simulation of Selective Angiography With Multidetector-Row Computed Tomography. Circulation, 2015, 131, e476-9.	1.6	2
36	Two-year vessel healing after everolimus-eluting stent implantation: Serial assessment by optical coherence tomography. Journal of Cardiology, 2015, 65, 298-304.	1.9	15

TOSHIRO SHINKE

#	Article	IF	CITATIONS
37	Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation. Circulation Journal, 2014, 78, 1882-1890.	1.6	17
38	Impact of Stent Platform of Paclitaxel-Eluting Stents. Circulation Journal, 2012, 76, 1880-1888.	1.6	21
39	Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel. Circulation Journal, 2012, 76, 2348-2355.	1.6	43
40	Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies. Journal of the American College of Cardiology, 2012, 59, 1058-1072.	2.8	1,530
41	Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart, 2011, 97, 1379-1384.	2.9	59
42	Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2009, 2, 459-466.	2.9	128
43	Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. European Heart Journal, 2007, 28, 961-967.	2.2	320